ARVN insider trading
NasdaqGS HealthcareARVINAS, INC.: insider trade history from SEC Form 4 filings.
About ARVINAS, INC.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Company website: www.arvinas.com
ARVN insider activity at a glance
FilingIQ tracks 376 insider transactions for ARVN in filings since Oct 1, 2018. The most recent transaction is dated Jun 24, 2026.
Across the full history, 23 open-market purchases
and 202 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ARVN insider trades is 55.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ARVN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ARVN?
- FilingIQ tracks 376 Form 4 insider transactions for ARVN (ARVINAS, INC.), covering filings from Oct 1, 2018 onwards. 0 of those are dated within the last 90 days.
- Are ARVN insiders net buyers or net sellers?
- Across the full Form 4 history for ARVN, 23 transactions (6%) were open-market purchases and 202 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ARVN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ARVN in?
- ARVINAS, INC. (ARVN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $867.80M.
Methodology & sources
Every ARVN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.